Skip to main content

Table 2 An overview of published findings investigating association of the 77C/G polymorphism with autoimmune disorders.

From: The CD45 77C/G allele is not associated with myasthenia gravis - a reassessment of the potential role of CD45 in autoimmunity

Study

Year

Population

Disease

Patients MAF(%) (n)

Controls MAF(%) (n)

OR

95% confidence interval for OR

Association

Jacobsen et. al. [20]

2000

Germany

MS

3.2 (219)

0.0 (189)

NA†

NA†

1.5 × 10-4

Jacobsen et. al. [20]

2000

Germany

MS

3.2 (108)

0.0 (114)

NA†

NA†

0.0058

Jacobsen et. al. [20]

2000

USA

MS

1.6 (122)

1.8 (244)

0.89

0.27-2.91

Not significant

Jacobsen et. al. [20]

2000

Germany

MS

3.3 (76)

0.4 (119)

8.06

0.93-69.68

0.0342

Barcellos et. al. [37]

2001

USA

MS

1.7 (450)

1.2 (253)

1.41

0.54-3.66

Not significant

Vorechovsky et. al. [38]

2001

Sweden

MS

1.5 (630)

1.4 (1044)

1.05

0.59-1.87

Not significant

Vorechovsky et. al. [38]

2001

Sweden

CVID

2.3 (44)

1.4 (1044)

1.60

0.38-6.78

Not significant

Vorechovsky et. al. [38]

2001

Sweden

IgAD

1.4 (148)

1.4 (1044)

0.94

0.33-2.69

Not significant

Vorechovsky et. al. [38]

2001

UK

CVID

1.5 (98)

0.9 (232)

1.79

0.40-8.06

Not significant

Vorechovsky et. al. [38]

2001

UK

IgAD

0.0 (17)

0.9 (232)

NA†

NA†

Not significant

Miterski et. al. [39]

2002

Germany

MS

0.8 (454)

1.4 (347)

0.53

0.20-1.40

Not significant

Wood et. al. [40]

2002

Germany

TID

0.2 (228)

1.3 (196)

0.17

0.02-1.46

Not significant

Wood et. al. [40]

2002

Germany

Graves

1.3 (297)

1.3 (196)

1.06

0.34-3.25

Not significant

Ballerini et. al.[27]

2002

Italy

MS

1.0 (194)

0.0 (222)

NA†

NA†

p = 0.02

Gomez-Lira et. al. [30]

2003

Italy

MS

1.2 (448)

0.9 (529)

1.30

0.55-3.08

Not significant

Schwinzer et. al. [31]

2003

Germany

SSca

3.7 (67)

0.7 (205)

5.26

1.24-22.31

p = 0.029

Schwinzer et. al. [31]

2003

Germany

SLE

2.0 (98)

0.7 (205)

2.83

0.63-12.75

Not significant

Vogel et. al. [32]

2003

Germany

AIHb

3.2 (190)

0.7 (210)

4.53

1.27-16.19

p = 0.015

Tackenberg et. al. [35]

2003

Germany

MG

0.6 (78)

0.0 (303)

NA†

NA†

Not significant

Nicholas et. al. [41]

2003

UK

MS

2.6 (330)

2.0 (197)

1.28

0.55-2.98

Not significant

Thude et. al. [42]

2004

Germany

TID

1.2 (165)

1.1 (220)

1.07

0.28-4.01

Not significant

Cocco et. al.[43]

2004

Sardinia

MS

1.0 (246)

0.7 (226)

1.54

0.37-6-47

Not significant

Vyshkina et. al. [28]

2004

USA

MS

NA (176)c

NA (NA)

NA

NA

p = 0.0342d

Esteghamat et. al. [44]

2005

Iran

AIHb

0.0 (70)

0.4 (140)

NA†

NA†

Not significant

Kirsten et. al. [45]

2008

Germany

SSca

0.6 (171)

1.4 (179)

0.42

0.08-2.16

Not significant

Pan-Hammarström et. al.[46]

2008

Sweden

IgAD

1.3 (232)

1.2 (913)

1.07

0.43-2.66

Not significant

Pan-Hammarström et. al.[46]

2008

Sweden

CVID

0.5 (91)

1.2 (913)

0.45

0.06-3.38

Not significant

Szvetko et. al. [34]

2009

Australia

MS

3.2 (155)

2.3 (171)

2.25

0.76-6.65

Not significant

  1. † The OR cannot be calculated for genotypes with some allele count of zero.
  2. a Systemic sclerosis
  3. b Autoimmune hepatitis
  4. c Number of families used to study transmission of G allele
  5. d Significance determined using 10,000 bootstrap samples in the software TRANSMIT version 2.5 after pedigree disequilibrium test failed to give a significant result